Development of lacosamide for the treatment of partial-onset seizures - Wikidata - wikimedia - TriplyDB

Development of lacosamide for the treatment of partial-onset seizures

Development of lacosamide for the treatment of partial-onset seizures

http://www.wikidata.org/entity/Q24629140

about

Lacosamide in status epilepticus: Systematic review of current evidence.The efficacy of lacosamide as monotherapy and adjunctive therapy in focal epilepsy and its use in status epilepticus: clinical trial evidence and experience Lacosamide: a review of its use as adjunctive therapy in the management of partial-onset seizures.Advances in epilepsy treatment: lacosamide pharmacokinetic profile.Clinical pharmacokinetic and pharmacodynamic profile of lacosamide.Efficacy and Tolerability of Lacosamide in the Treatment of Children With Refractory Generalized Epilepsy.Acute or chronic use of lacosamide does not alter its distribution between serum and cerebrospinal fluid.Lacosamide inhibits calcitonin gene-related peptide production and release at trigeminal level in the rat.Lacosamide treatment of childhood refractory focal epilepsy: the first reported side effect in paediatric patients.Cognitive effects of lacosamide as adjunctive therapy in refractory epilepsy.Treatment with lacosamide impedes generalized seizures in a rodent model of cortical dysplasia.Lacosamide-Induced Recurrent Ventricular Tachycardia in the Acute Care Setting.

P2860

Q30399934-0163FDBE-6166-411F-975F-3F51DF452276 Q37722778-8367CA50-813B-41C6-9F71-5DCEABC6DBB9 Q38160816-9AE33626-0F22-41DD-81F4-B36C5F74F95A Q38244248-233C2359-619E-4813-A96E-6A2600BF4EDF Q38468591-4E06EDB7-4A2B-4793-B5D6-530D292330E3 Q39989931-EE353AA5-6451-4AC2-AEC8-F3DE427CDA49 Q40651545-B133125D-5D08-402C-9AAC-770AF3D8E2B0 Q49053027-9623F3BC-1D61-499C-8CD6-8BCE1D74BD28 Q50201563-7442CFEB-48AF-4F7D-96EE-FA839688E020 Q50599628-003CE60C-3BA1-4AFD-B4AA-1524C9EB31DE Q51823925-7A2A3FDA-56A7-4A16-95DC-289BC5996659 Q52696502-C1B53DAB-108D-4620-869C-8686405A2C18

P2860

Development of lacosamide for the treatment of partial-onset seizures

http://www.wikidata.org/entity/Q24629140

description

2013 nî lūn-bûn

@nan

2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Development of lacosamide for the treatment of partial-onset seizures

@ast

Development of lacosamide for the treatment of partial-onset seizures

@en

Development of lacosamide for the treatment of partial-onset seizures

@nl

type

label

Development of lacosamide for the treatment of partial-onset seizures

@ast

Development of lacosamide for the treatment of partial-onset seizures

@en

Development of lacosamide for the treatment of partial-onset seizures

@nl

prefLabel

Development of lacosamide for the treatment of partial-onset seizures

@ast

Development of lacosamide for the treatment of partial-onset seizures

@en

Development of lacosamide for the treatment of partial-onset seizures

@nl

P1433

Q24629140-F18B7062-86EE-438E-B5F8-0BA385288807

P1476

Q24629140-1C3DE241-65A7-41B6-9ADB-B58F655C3CDD

P2093

Q24629140-09EA6AE2-2E31-4C73-9F19-5E2666917A12

Q24629140-5F7380B4-52DD-4472-B85C-C61727F3ED88

Q24629140-6F76DE30-5E4C-4553-AF32-4A7604CC09E3

Q24629140-9CCD6D05-0045-42DD-AE78-FD03795BB72F

Q24629140-A6D36596-071E-4F66-9870-8712B18F2010

Q24629140-D026A22C-0828-4BE2-B832-69A8CA5DB038

P275

Q24629140-32F09A13-9079-4787-8C41-A199B73A1A50

P2860

Q24629140-0261E973-40E9-4206-9650-632F4A45328D

Q24629140-02A8E059-CE27-4A61-B195-61AB031A6A67

Q24629140-1864FAB6-6870-4BEE-A8C1-A42E3B1B9909

Q24629140-192F86A1-EDB1-4705-A425-222404A325F3

Q24629140-1D3D0FE0-AAFF-4223-BE6F-E57B3FE617F7

Q24629140-1D7DC209-C603-4799-80D6-5C6A6741138B

Q24629140-24350A4B-ED69-4B20-8CB8-4280A5E5E114

Q24629140-2D03E434-4159-44BD-A0D6-25C204A104D3

Q24629140-2D917027-341D-4437-B7FA-EC739843F794

Q24629140-304212EE-E788-451E-9FFB-7CB3595BE2D9

P304

Q24629140-5CF278A3-4EE5-460E-A4C5-1A0D4E43FB31

P31

Q24629140-213AC7D7-3E11-42E6-A340-B336AF6793D9

Q24629140-8259DA67-CE67-453F-86F3-F625318AE510

P356

Q24629140-1862FC0B-E7D6-4BFE-A540-4EDB67F10318

P407

Q24629140-20E54755-DD53-490A-861D-E96963BD876F

P433

Q24629140-CB337C1B-2AC9-48F1-BB22-DA20CFDF3DB9

P478

Q24629140-37268B7C-2438-4667-85B8-FA47B7F38BBD

P5008

Q24629140-8B58C10E-70C2-4EB2-B247-42C433726CC7

P577

Q24629140-561FA144-4003-4890-830F-27084D7AB9A1

Q24629140-5E455B34-D780-469B-AAD2-1827CD061BE9

P5875

Q24629140-476DD46D-DA8F-4DA3-A65C-91075ADC6219

P698

Q24629140-3BE841F7-4D87-4B02-ABF1-9488FD4690B2

P921

Q24629140-126CFBC2-0FEE-4AD4-B60B-183669B6349F

Q24629140-80945C5F-2ACC-45EF-A2CC-6F4C24F6B510

Q24629140-C187829B-4045-4E5F-88EE-A9B22833D01C

P932

Q24629140-6F024C9D-D307-4F8B-A39C-D5F2F0C9B1EB

P356

P1433

Annals of the New York Academy of Sciences

P1476

Development of lacosamide for the treatment of partial-onset seizures

@en

P2093

David Hebert

http://www.w3.org/2001/XMLSchema#string

Francois-Xavier Mathy

http://www.w3.org/2001/XMLSchema#string

James Zackheim

http://www.w3.org/2001/XMLSchema#string

Kelly Simontacchi

http://www.w3.org/2001/XMLSchema#string

Pamela Doty

http://www.w3.org/2001/XMLSchema#string

William Byrnes

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 2.5 Unported

P2860

The adverse event profile of lacosamide: a systematic review and meta-analysis of randomized controlled trials

Safety and tolerability of adjunctive lacosamide intravenous loading dose in lacosamide-naive patients with partial-onset seizures.

Efficacy and tolerability of the new antiepileptic drugs, I: Treatment of new-onset epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society.

ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes.

A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs.

In silico docking and electrophysiological characterization of lacosamide binding sites on collapsin response mediator protein-2 identifies a pocket important in modulating sodium channel slow inactivation

Lacosamide, a novel anti-convulsant drug, shows efficacy with a wide safety margin in rodent models for epilepsy.

Lacosamide: a review of preclinical properties.

Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures.

Intravenous lacosamide as replacement for oral lacosamide in patients with partial-onset seizures.

P304

56-68

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/NYAS.12213

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

1291

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2013-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

249965205

http://www.w3.org/2001/XMLSchema#string

P698

23859801

http://www.w3.org/2001/XMLSchema#string

P921

carboxylic acid

P932

3759704

http://www.w3.org/2001/XMLSchema#string